ArticleBritish journal of pharmacology2012

Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates.

A M Filppula et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.